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"Here, the images of a laboratory mouse and a scientist are combined, because they are 
connected to each other." 
Andrei Kharkevich 
      
 
  
  
  
ABSTRACT 
Parkinson’s disease (PD) is a common neurodegenerative disorder, typically characterized by 
the progressive death of midbrain dopaminergic neurons projecting from the substantia nigra 
to other areas within the basal ganglia. Historically, PD has been diagnosed as a purely motor 
disorder dominated by bradykinesia (slowness of movement), rigidity, resting tremor, and 
postural instability. While there are no approved disease-modifying therapies, these 
symptoms can be counteracted by dopamine replacement therapies based on the use of L-
Dopa and dopamine receptor agonists.  
In the past decades, the classic view of PD as an exclusively motor disease has been 
challenged by increasing evidence showing that patients display a wide range of non-motor 
symptoms (NMS), including hyposmia, sleep disturbances, cognitive impairment, depression 
and anxiety. These ailments often appear in the early, pre-motor stage of the disease and 
progressively worsen, significantly affecting the patient’s quality of life. The 
neuropathological mechanisms underlying NMS are still poorly understood, but clinical 
findings have consistently shown the involvement of both the dopaminergic and non-
dopaminergic systems. Interestingly, these symptoms only partially respond to dopaminergic 
treatments used to handle motor deficits, complicating the pharmacological management of 
patients. The increasing demand for more effective therapies for NMS indicates the 
importance of developing translational approaches based on the use of appropriate animal 
models.  
In this thesis, we developed and validated a mouse model of PD for the study of NMS. This 
model is characterized by a bilateral partial degeneration of the dopaminergic system 
achieved through intra-striatal injection of 6-hydroxydopamine (6-OHDA). We found that 
this model presents only subtle gait modifications reminiscent of early stage PD. Most 
importantly, we showed that the 6-OHDA lesion impairs olfactory discrimination, disrupts 
circadian rhythm, causes long-term memory deficits, as well as depression- and anxiety-like 
behaviors. Using a combination of anatomical and pharmacological approaches, we validated 
this model for the study of NMS and described the effects produced on these deficits by 
administration of dopaminergic and non-dopaminergic drugs. 
Altogether, these studies provide a well-characterized tool for the study of NMS in PD, as 
well as information on molecular and neural targets implicated, thereby opening new vistas 
for the design of broader therapeutic interventions.   
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1 INTRODUCTION 
 
1.1 THE EXPANDING SYMPTOMATOLOGY OF PARKINSON’S DISEASE 
Parkinson’s disease (PD) is a complex neurological disorder classically characterized by the 
dopaminergic denervation of the basal ganglia, due to the death of dopamine-producing cells 
in the substantia nigra (SN). The resulting dopamine deficiency leads to the parkinsonian 
motor syndrome described as poverty and slowness of movement paralleled by increased 
muscle tone. In the clinical practice, those cardinal symptoms are referred to as bradykinesia 
and muscular rigidity, and are usually accompanied by tremor at rest and postural instability. 
Although PD diagnostic criteria are classically focused on motor dysfunctions, the 
conceptualization of the disease continuously evolved since Dr. James Parkinson’s first 
detailed description two centuries ago1. Currently, the symptomatology of the disease is 
recognized as heterogeneous, involving neurotransmitters other than dopamine and regions of 
the nervous system outside the basal ganglia. Moreover, it is now well accepted that the 
disease has a slow and progressive nature, which begins decades before diagnosis can be 
made and manifests itself with a broad range of deficits including non-motor symptoms 
(NMS)2. 
NMS comprise autonomic dysfunctions such as cardiovascular, urogenital and gastro-
intestinal manifestations, sleep disorders with dream enactment behavior and daytime 
somnolence, sensory disorders such as hyposmia and chronic pain, cognitive impairment and 
neuropsychiatric conditions including depression and anxiety. Importantly, NMS can precede 
the typical parkinsonian motor syndrome, which develops only after approximately 70% of 
the SN dopaminergic cells are lost3.  
PD is often viewed as a synonym to motor parkinsonism and its diagnostic criteria consider 
most NMS as an early sign of disease onset, medically referred to as a prodrome4. 
Consequently, NMS are often under-recognized since patients remain unaware that some of 
their behaviors may be related to PD, embarrassed to discuss NMS that are not prompted by 
the doctor and even lack time for disclosure when attention is focused on motoric criteria5. As 
a result, clinicians often fail to recognize NMS during consultations6. 
Recently, the International Parkinson and Movement Disorders Society presented a new 
guideline for PD diagnosis, with the aim of updating clinical practice and standardizing the 
process across centers. Amongst the changes, dementia was removed7 as an exclusion 
criterion for PD. In parallel, they proposed a set of criteria for the diagnosis of prodromal PD 
which, as for now, is only intended for research. These changes highlight a much-needed 
expansion of the disease concept, and the prodromal PD criteria have raised an interesting 
discussion among scientists regarding its feasability8–10. Given the advances and 
controversies, it is likely that the upcoming years will see an interesting debate concerning 
non-motor features of PD.  
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Clinical and experimental research on the prodromal phase have important implications, not 
only for the identification of early pathogenic events, but also for optimizing the success of 
future therapeutic strategies, as well as developing treatments against non-motor features 
which represent a significant clinical burden. 
 
1.2 DOPAMINE REPLACEMENT THERAPY: A ‘GOLEM’ IN NEUROSCIENCE 
With disease-modifying treatments remaining elusive, the management of PD symptoms is 
often achieved through dopaminergic replacement therapies that aim at increasing dopamine 
availability or directly stimulating dopamine receptors. In this context, administration of the 
dopamine precursor L-Dopa (L-3,4-dihydroxyphenylalanine), is the gold standard treatment 
approach (in fact, L-Dopa responsiveness is part of the diagnostic criteria). 
L-Dopa effect in PD patients was initially demonstrated in 1961. This first successful clinical 
trial was preceded by 3 major scientific breakthroughs, all done in a matter of five years: 
dopamine was shown to be present in the brain, to be enriched in the mammalian basal 
ganglia and to be dramatically reduced in the brain of parkinsonian patients. As a result of 
these seminal articles, the research field was rapidly pushed forward (see history11,12) causing 
an increase in topic-related publications in the years that followed (see blue bars in Figure 1).  
Since then, we have gathered an enormous amount of information concerning the 
pathophysiology of this disease. Indeed, we have learnt that the disease develops from a 
complicated interplay between genetics and environment, with humans being exclusively 
affected by a time-dependent cascade of events ultimately leading to lysosomal dysfunction 
and α-synuclein aggregation13. Moreover, we learnt that L-Dopa affords symptomatic relief 
for a subset of motor deficits, that it does not modify the progressive neuronal degeneration 
and that prolonged administration of this drug results in the emergence of a range of 
undesirable side-effects14. Despite these limits, to this day, L-Dopa remains the most 
efficacious treatment for the symptomatic control of PD and all other conventional 
approaches still rely on the basic concept of dopaminergic replacement strategies one way or 
another. In fact, in addition to L-Dopa, the current PD pharmacotherapy includes the use of 
dopamine agonists to directly activate dopamine receptors, monoamine oxidase B (MAO-B) 
and catechol-O-methyl transferase inhibitors to prevent dopamine metabolic degradation and 
anticholinergic agents to correct the imbalance between dopamine and acetylcholine.  
Fast forward from 1961 to 2018 and here we remain, the dopaminergic replacement therapy 
is likened to a Golem, a creature from mythology, powerful yet potentially dangerous, a 
helpful creature that may yet run amok at any given moment. We cannot stop disease 
progression, yet PD symptoms are mostly under the Golem’s control.  
In fact, thanks to dopamine replacement therapies, motor parkinsonism no longer 
overshadows the non-motor symptomatology, as indicated by a large body of evidence 
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suggesting that the global burden of NMS in PD has a greater impact on life quality than 
motor symptoms15–18. 
 
Braak stages of PD19                                                                                                                                         Perspective Box 
The pathological aggregation of α-synuclein into toxic fibrils and deposits is a hallmark of the disease, being 
accompanied and followed by neuronal degeneration in PD. According to the current concept, PD is a 
synucleinopathy that propagates in an ascending pattern via directly connected neuronal pathways. Based on 
these progressive events, the course of the pathology can be divided into stages, as proposed by Braak and 
colleagues. Initially, the PD pathology is only detected in the olfactory bulb and in two basal cranial nerves 
nuclei, i.e., the glossopharyngeal and the vagal nerve (stage 1). This corresponds to the development of 
hyposmia and autonomic dysfunctions, including obstipation. Successively, the pathology propagates into the 
pontine areas of the locus coeruleus, the raphe nuclei, and the reticular formation (stage 2). This brainstem 
affection may cause REM sleep disorder, which is one of the most specific predictor of PD. The following 
stage is characterized by the involvement of the SN and the anterior olfactory nucleus (stage 3), whereas 
significant rates of degenerating neurons in the SN pars compacta are only seen later on (stage 4). Motor 
symptoms only emerge at stage 4 or later.  
This view has been challenged by some20.                                                                              
 
The broad range of NMS and their complex pathophysiology will be discussed in detail in 
individual sections within this thesis. Importantly, a subset of NMS is refractory to L-Dopa 
treatment21, while others may even worsen due to dopamine replacement therapies. For 
instance, the increase of dopamine synthesis produced by L-Dopa treatment has been shown 
to reduce serotonin levels in the PD brain22,23 and serotonergic disruption plays a prominent 
role in the expression of neuropsychiatric symptoms occurring at the onset of the disease24 
(note that serotonergic neurons are capable of decarboxylating L-Dopa into dopamine and 
then releasing it. This process is cytotoxic to serotoninergic cells due to oxidative 
mechanisms25). 
The expanding symptomatology of PD has triggered a growing interest in clinical and 
preclinical research on NMS and highlighted the need to develop and validate new preclinical 
models (see red bars in fig.1). The focus of this thesis is to bridge the gap between researchers 
and clinicians by optimizing an animal model for the study of non-motor symptoms in 
Parkinson’s disease. 
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Figure 1. Diagram showing the total number of PD-related publications (grey bars) as compared to the number 
of NMS-related publications (red bars). Note the spike in PD publications between 1970-1973 (light blue bars), 
following the discovery of L-Dopa as a therapy for PD patients. During that period, the most frequent words on 
article titles were “L-Dopa”, “treatment” and “patients”, in order (inlet). Currently, the number of publications 
on NMS related topics is still low in comparison to the total number of PD related publications. Data acquired 
from PubMed, adjusted following the MeSH Database and examined using open-ended ‘free text’ analyses on 
JMP statistical software. 
 
1.3 REQUIREMENTS FOR PRECLINICAL RESEARCH 
An animal model should fulfill a set of criteria to be considered relevant for the study of the 
corresponding human pathology. Predictive validity relies on pharmacological correlation, 
where the treatment known to be effective in humans should improve symptoms in animals. 
In other words, it corresponds to the ability of the model to respond to the treatments, as 
expected based on human data. Face validity refers to the degree of behavioral and 
anatomical similarity between the model and the disorder that is modeled. Finally, construct 
validity regards the accuracy with which the model measures what it is intended to measure. 
In other words, it indicates the correspondence between symptoms and underlying neuronal 
mechanisms in both human and animal species. Together, these validity checks ensure the 
predictive power of an animal model26. 
It is important to note that the use of animal models in research requires a deep knowledge of 
their intrinsic limitations. Within the frame of this thesis, one must be aware that PD does not 
occur spontaneously in animals other than humans. However, despite the human-specific 
nature of PD, the characteristic features of the disease can be mimicked in animals (rodents 
and non-human primates) through administration of various neurotoxins and drugs that 
disturb dopaminergic neurotransmission27 or alternatively by genetic approaches28. The 
understanding that preclinical models are an incomplete representation of the human 
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condition and that the modeling approach is contingent to the scientific questions that it aims 
to address, is a fundamental prerequisite for translational research (see reviews29–31). 
In the specific context of NMS, it has to be considered that the occurrence of these symptoms 
in animals is studied through behavioral tests that, by definition, require a relatively intact 
motor repertoire. For this reason, an appropriate animal model of NMS should not display the 
drastic motor components of PD. 
1.3.1 Ethical considerations 
Ethical considerations are an important aspect when choosing an adequate preclinical model. 
First, no responsible scientist wants to use animals or cause them unnecessary suffering if it 
can be avoided, be it physical or emotional stress. Therefore, the use of animals in research 
should comply with the ethical framework established by governmental institutions, animal 
welfare groups, veterinaries and experts in ethics. Second, living systems are extremely 
complex and as for now, we lack alternatives to study interrelated processes occurring in the 
central nervous system. 
 
1.4 THE USE OF 6-OHDA 
With the nigrostriatal degeneration being recognized as the primary pathogenic factor in 
PD32, the path was paved for the search of animal models. Interestingly, shortly after the 
discovery of the L-Dopa effect, the 6-OHDA (6-hydroxydopamine) neurotoxin was 
described33,34. 
6-OHDA is a structural analogue of dopamine and noradrenaline, and exerts its toxic effects 
on catecholaminergic neurons by inducing mitochondrial oxidative stress and ultimately cell 
death35. Due to its inability to cross the blood-brain barrier, 6-OHDA has to be injected 
directly into the brain (via stereotaxic surgery). Ungerstedt36 pioneered the use of 6-OHDA to 
produce the PD phenotype by injecting the toxin bilaterally into the SN of the rat, obtaining 
an animal model with impaired voluntary movements and high mortality rate. Following this 
study, several protocols of 6-OHDA administration have been published and this neurotoxin 
has become a widely used approach for modeling parkinsonism in rodents. 
The popularity of the 6-OHDA model lies on its ability to mimic the dramatic loss of 
dopaminergic neurons in PD. The resulting dopaminergic depletion remains stable for several 
months, thereby simplifying the experimental evaluation (particularities are on section 1.5). 
Moreover, 6-OHDA can be used to model distinct stages of the human pathology, simply by 
varying the localization and extent of the lesion. 
However, as every experimental model, the 6-OHDA-induced PD model has its limitations. 
The toxin has an acute effect and selectively kills catecholaminergic cells, consequently, it 
does not replicate the full spectrum of clinical PD features. For instance, the degeneration of 
cholinergic neurons37 is not fully replicated and the serotoninergic system is only partially 
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affected38. In addition, although 6-OHDA causes dopaminergic depletion, it fails to develop 
other pathological hallmarks of the disease, such as the appearance of Lewy bodies 
containing α-synuclein aggregates39. 
Despite those limitations, the 6-OHDA approach represents one of the best and most widely 
used PD rodent models and has been an essential tool for testing a variety of anti-
parkinsonian treatments over the years. 
 
1.5 THE BILATERAL PARTIAL 6-OHDA MODEL OF PARKINSON’S DISEASE 
In the preclinical practice, the striatal dopaminergic depletion can be induced by infusing 6-
OHDA in one of three different brain areas, the dopaminergic cell bodies in the substantia 
nigra (SN), the medial forebrain bundle connecting those cells to their targeted regions, 
and the striatum, which is the most prominent release site for dopamine in the basal ganglia. 
Researchers can perform either unilateral or bilateral lesions. Unilateral lesions are mostly 
used for the study of motor parkinsonism, whereas bilateral lesions are the appropriate choice 
for the study of NMS (discussed on section 1.6). Importantly, bilateral lesions that incur total 
dopaminergic depletion are not compatible with life. 
The substantia nigra is a relatively small structure. It has a thin profile, being elongated on 
the rostro-caudal direction and is neighbored by the ventral tegmental area. Anatomical 
descriptions of the disease course showed that in early PD the ventral tier is more affected 
than the dorsal tier3,40. Moreover, injections of 6-OHDA in the medial SN result in larger cell 
loss41,42. Taken together, these anatomical factors make it difficult to generate a partial 
depletion of dopamine by targeting the SN (see structure in red on fig.2).  
 
SN partial lesion with 6-OHDA and sprouting                                                                                             Perspective Box  
There is evidence in the literature indicating that ‘medium-size’ lesions done in the SN (< 70% of 
dopaminergic loss) are accompanied by re-innervation of the striatum, via axonal sprouting43–47 (also the 
effect of drug treatment in PD models48 and evidence in patients49) with consequent motor improvement47 
(measured as rotational bias in unilaterally lesioned rodents). Interestingly, the process is described as being 
driven by new axons entering the striatum rather than sprouting of remaining axons from spared cells50. 
Thereafter, long-term studies must always report lesion size and stability. 
 
The medial forebrain bundle is a dense neural pathway that contains, amongst others, the 
ascending fibers of dopaminergic cells projecting from the SN to striatal areas. The axons of 
dopaminergic cells are variculated and contain the dopamine transporter, which accounts for 
the uptake of 6-OHDA into the cells. Due to its anatomical connections, this area is the most 
frequent injection site used to generate unilateral total lesions, yet researchers have shown 
that dose-dependent loss, although technically difficult, can also be accomplished51–53. 
  13 
Whereas, the direct injection of 6-OHDA into the SN or medial forebrain bundle yields a 
rapid death of dopaminergic cell bodies, followed by degeneration of striatal terminals, toxin 
injections into the striatum produce a slower degradation of nigrostriatal fibers through a 
retrograde mechanism that occurs over a period of weeks54–57. Time-course studies with total 
unilateral striatal lesion in rodents reported that the initial damage to the dopaminergic axons 
occurs within 24 hours, with the extent of the lesion-site peaking at the third week. In parallel 
a retrograde process is taking place, causing a loss of dopaminergic cell bodies that peaks 
within 28 days (rat54 and mice58). At this final stage, the lesion remains stable for a prolonged 
period of time55–57.  
Compared to SN and medial forebrain bundle, the administration of 6-OHDA into the 
striatum is easier to perform, due to its relatively larger size and dorsal position. These 
anatomical features allow for a better control of the lesion extent, critical when the goal is to 
achieve a partial degeneration. Importantly, this area can be reliably targeted inducing NMS 
in the absence of severe motor impairment (discussed below) (see structure in blue on fig.2), 
well mimicking the initial dopaminergic deficiency observed in the dorsolateral striatum of 
PD patients59. 
 
 
Figure 2. Schematic mouse brain depicting the anatomical location of the striatum and substantia nigra, two 
areas which are commonly targeted by 6-OHDA administration. Note how the striatum, in blue, is a much larger 
structure allowing for easier access and reproducibility of partial lesions (scale bar as indicated).  
 
Regardless of the injection site, the extent of the lesion can be manipulated by changing the 
toxin concentration and volume of injection, variables that differ between mice and rats. It 
has also been shown that both young and aged male rats are more susceptible to 6-OHDA 
insult compared to females (SN, unilateral lesions)60. Subsequently, the researcher must 
consider all above-mentioned factors in order to reliably generate a partial lesion model of 
NMS in PD.  
For an adequate modeling of NMS in PD, the use of bilateral rather than unilateral 
dopaminergic lesion is needed to avoid compensatory effects between lesioned and non-
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lesioned hemispheres61. Moreover, the lesion must be partial to preserve motor repertoire and 
allow an appropriate evaluation of behavioral performance.  
To our knowledge, the first study that used a bilateral 6-OHDA lesion for the sole purpose of 
modeling NMS in PD was published in 2005 by Ferro41 and colleagues. In this work, the 
toxin was injected at high concentrations in the substantia nigra of rats, resulting in high 
levels of dopaminergic depletion with cell death in both the SN and the ventral tegmental 
area. Moreover, the protocol of injection resulted in high mortality rates, with almost half of 
animals being lost within the first 20 days. The high mortality rate in 6-OHDA lesioned 
animals had already been reported previously62–65 and is thought to be due to reduced feeding 
motivation (i.e., adipsia and aphagia), consequent dehydration and weight loss62,66. Hence, 
Ferro et al., were able to test only the less severely lesioned rats (~80% dopaminergic 
depletion) and described the presence of cognitive deficits (as assessed in the water maze 
task). However, the protocol induced a significant impairment in spontaneous locomotion, a 
confounding factor that limited their behavioral profiling.  
In 2008, Tadaiesky67 et al. carried out the first comprehensive study where rats were 
bilaterally injected in the dorsal striatum to achieve a 60% decrease in the number of 
dopaminergic cells within the substantia nigra and 40% decrease in the density of striatal 
tyrosine hydroxylase (TH, the rate-limiting enzyme of catecholamine synthesis). Following 
the lesion, rats showed depressive-like behaviors, anhedonia and behavioral despair, as 
indicated by diminished sucrose consumption and increased immobility in the forced swim 
test. Furthermore, lesioned rats had increased anxiety as determined by reduced entries to the 
open arms of the elevated plus maze. Finally, lesioned rats needed more time to find the 
platform in the water maze task and failed to display social odor recognition despite having 
normal olfactory function. These features indicate a deficit in cognitive function. Importantly, 
in this model the described NMS occurred in the absence of changes in spontaneous 
locomotion, as measured with the open field test. 
Up to now, rats are the species of choice to model NMS with 6-OHDA partial lesions. This is 
not only a legacy of the first experiments but also a result of the overall reduced survival 
observed when bilateral lesions are performed in mice. Both adipsia and aphagia were 
reported since the start of 6-OHDA use in the central nervous system68 and while rats can be 
force fed, mice cannot withstand such approach. In spite of these limitations, the use of mice 
to study NMS is often preferable, since this species offers more options in combination with 
transgenic approaches, giving access to a full range of modern research tools.  
In conclusion, partial lesions of the nigrostriatal dopaminergic system are considered to be 
analogous to the early stages of human Parkinson’s disease and can be induced reliably by 
striatal injection of 6-OHDA. Technically, the main challenge is to find the correct 6-OHDA 
concentration needed to achieve NMS without confounding motor effects and to reduce post-
operative mortality. Importantly, the generation of reliable mouse models of NMS would 
foster further investigation by reducing costs and opening a door to the use of a large array of 
genetically modified animals as the field develops.  
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1.6 A MOUSE MODEL TO STUDY NON-MOTOR SYMPTOMS IN PD: INITIAL 
RESULTS 
In this thesis, we studied NMS using a mouse model initially developed in our research group 
by Bonito-Oliva and colleagues69. This model was generated by a bilateral injection of 6-
OHDA in the dorsolateral striatum (4 µg/µl; 1 µl/site), resulting in a 70% striatal reduction of 
dopaminergic fibers and 80% decrease in hippocampal TH immunoreactivity. The bilateral 
lesion had no effect on spontaneous motor activity but was accompanied by cognitive deficit, 
as assessed by behavioral and electrophysiological experiments.  
The hippocampus is involved in cognitive function and receives both dopaminergic and 
noradrenergic input. Noradrenergic innervation originates mainly from the locus coeruleus 
whereas dopaminergic fibers originate from the ventral tegmental area (VTA) and substantia 
nigra pars compacta (SNc)70, both important for hippocampus-dependent learning and 
memory71–73. Due to 6-OHDA-induced toxicity, and in line with the above-mentioned results, 
TH expressing cells in the substantia nigra and locus coeruleus dropped by 65% and 25%, 
respectively, prompting the authors to perform a series of experiments in order to investigate 
the relative role of these two neurotransmitters in cognitive performance. For this aim they 
pretreated lesioned mice with desipramine, a blocker of the noradrenaline transporter, which 
protects noradrenergic fibers from the toxin. Their results showed that the cognitive deficit 
was still present even after desipramine pretreatment, indicating the unique role of dopamine 
in this memory task.  
Follow-up experiments showed that the cognitive deficit was paralleled by reduced synaptic 
plasticity in the dentate gyrus, a region of the hippocampus that plays a key role in learning74. 
The deficit in synaptic plasticity was counteracted by activation of hippocampal dopamine 
D1 receptors (through administration of L-Dopa and SKF81297, a selective D1 receptor 
agonist75) while D2 / D3 receptor activation (through administration of pramipexole) resulted 
ineffective. Finally, synaptic plasticity was dependent on intact extracellular signal-regulated 
kinase (ERK) signaling. Importantly, ERK signaling pathways are implicated in gene 
expression including immediate early genes, which are in turn involved in various forms of 
synaptic plasticity76,77. 
In summary, the initial article described a new mouse model for the study of cognitive 
deficits in PD and showed that dopaminergic depletion, though only partial, is sufficient to 
cause cognitive impairment, which is particularly dependent on D1 receptor activation and 
ERK signaling in the hippocampus. 
 
 
 
 
 16 
The direct and indirect pathway                                                                                                                      Perspective Box 
The basal ganglia are subcortical structures that coordinate vital behaviors including movement. The striatum 
receives the majority of the basal ganglia input, and projects to the output nuclei via two pathways that work 
concomitantly to modulate behavior. D1 receptor expressing striatal medium spiny neurons project to the 
substantia nigra pars reticulata, whereas, D2 receptor medium spiny neurons project to the globus pallidus 
pars externa. Classical functional models of the basal ganglia propose that the direct and indirect pathways 
exert opposing effects on motor behavior; specifically, activation of the direct pathway increases locomotor 
activity (via D1-expressing cells), whereas the indirect pathway suppresses motor activity by exerting a tonic 
inhibitory tone (via D2-expressing cells). This model posits that any weakening of the direct pathway, or any 
strengthening of the indirect pathway, will result in poverty and slowness of movement which are cardinal 
features in PD78. 
Dopamine D1 receptor expressing cells and the antiparkinsonian effect                                                     
L-Dopa’s antiparkinsonian effect occurs upon its first dose and is mediated by activating dopaminergic 
receptors. However, precisely which dopaminergic receptor type is primarily responsible for L-Dopa’s effect 
is usually not defined in the literature79–81. The clinical use of D2 receptor agonists, such as pramipexole, but 
not D1 agonists82,83 to treat parkinsonism may suggest that D2 receptors in the indirect pathway are the 
primary mediator of the therapeutic effects of L-Dopa. However, experimental studies have demonstrated a 
critical role for the D1 receptor-expressing medium spiny neurons, originating from the direct pathway, to the 
promotion of motor activity84–87. Therefore, D1 receptors are crucial for the motoric recovery observed in PD 
patients after L-Dopa treatment.  
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2 AIMS 
 
The overall goal of this thesis was to investigate the behavioral effects of a bilateral partial 
striatal 6-OHDA lesion, and to optimize a reliable method for the preclinical study of NMS in 
PD. 
In order to achieve this objective, our first aim was to perform a series of behavioral tests and 
anatomical analyses to provide face validity, by showing the degree of similarity between the 
proposed model and the NMS features observed in PD patients. 
Upon identification of appropriate behavioral correlates, our second aim was to assess 
predictive validity by showing that pharmacological treatments known to be effective in 
patients improved symptoms in our mouse model. 
Finally, in the third aim we provided construct validity by appropriately selecting 
protocols that identify the correspondence between symptoms and the underlying neuronal 
mechanisms based on literature regarding both clinical data and other pre-clinical models. 
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3 RESULTS AND DISCUSSION 
 
3.1 INCREASING SURVIVAL OF CATECHOLAMINE-DEPLETED RODENTS 
(manuscript in preparation) 
As previously discussed, catecholaminergic lesions induced by 6-OHDA administration are 
often associated with lower rates of survival, mainly caused by adipsia and aphagia88–90 and 
have been described as strikingly similar to the lateral hypothalamic syndrome (read more91). 
Animal loss due to lesioning varies between 20% and 50% amongst articles and in many 
cases, due to conflict of interest, is not clearly reported. 
On the other hand, the brain is incredibly resilient to insult and low extent lesions often lack 
clear behavioral output. In between the system’s resilience and a model with measurable 
NMS, lies the success of a NMS model of PD. For instance, genetic animal models of PD 
with progressive dopamine degeneration, usually start to show NMS once cell loss achieves 
the 70% range. However, because of the progressive nature of these models, cells continue to 
die, motor impairment becomes salient and ultimately animals are sacrificed due to humane 
end point (for example see92). 
Throughout this project, we have conceptualized and then introduced a series of steps to aid 
recovery, reduce post-operative stress and ultimately increase survival of 6-OHDA lesioned 
mice. All procedures were approved by the local ethical committee (Stockholm Norra 
Djuretiska nämnd) and followed the EU directive (2010/63/EU). During the last 4 years, we 
kept a detailed description of each mouse used in our experiments, including general 
information regarding health status and perioperative care from one week pre-surgery to three 
weeks post-surgery.  
The entire project (including all trial experiments, 4 published articles and three papers in 
preparation) employed 996 mice. Approximately half of the animals were treated with the 
standard approved protocol, while for the other half, an ‘Enhanced Care (EC) protocol’ was 
applied. Survival curves for both groups were compared with the Kaplan-Meier method93–95, 
a statistical approach common to clinical trials, and our results show that the EC protocol 
increases survival rates, thereby reducing the number of mice needed in a project (fig.3). 
Moreover, the EC protocol includes a series of steps that respect the prerequisite of simple 
infrastructure and low associated costs. The details regarding the EC protocol are part of a 
manuscript in preparation, the manuscript describes the perioperative care and contains a 
series of statistical analyses that allowed us to examine which factors were mainly predictive 
of survival.   
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Figure 3. Tailored perioperative care enhances survival of mice with depletion of the catecholaminergic system. 
(a) Pie chart showing the percentage of mice that underwent either the Standard Care (SC) or the Enhanced Care 
(EC) protocol. For each group, mice that completed the experiments, reached humane end point or were lost 
during the recovery period (i.e., unmediated death) are graphed. (b) Survival curves of control (Sham, n = 176) 
and Lesion (n = 409) mice treated according to the SC protocol following bilateral partial lesion of the 
dorsolateral striatum with 6-OHDA. Matel-Cox test (Logrank analyses) showed higher mortality risk for the 
Lesion group (**** p < 0.0001) compared to Sham. (c) Survival curves of Sham (n = 155) and Lesion (n = 256) 
mice treated according to EC protocol. Note the improved survival rate of Lesion mice. Matel-Cox test (Logrank 
analyses) indicates that Lesion mice are still at higher hazard risk (Sham vs Lesion, * p = 0.025). Yet, 
comparison of the survival rates between Lesion groups treated with SC (dashed line) and EC (light blue) show a 
significant improvement (**** p < 0.0001). The proposed protocol reduces mortality from 20% to 5%. Graphs 
in b and c show survival percentages plotted with the Kaplan-Meier method, with survival curves represented by 
lines and SEM plotted as asymmetrical shadow zones (no subjects were censored). Graphpad prism software. 
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3.2 BRAIN WIDE EFFECTS OF STRIATAL 6-OHDA LESION                   
(manuscript in preparation) 
To better understand which brain areas are affected by the intrastriatal injection of 6-OHDA, 
we performed a brain wide analysis of TH immunoreactivity in lesion and sham operated 
mice, followed by a comparison of expression levels. This project contains the re-
construction of a whole-brain map for the 6-OHDA induced TH depletion and allowed us to 
pin-point affected areas and identify a variety of new brain regions that hold interest for the 
study on NMS. 
Dopamine is produced in the cytosol by the TH-mediated enzymatic conversion of L-tyrosine 
into L-Dopa, which in turn, is converted into dopamine by the aromatic L-amino acid 
decarboxylase96,97. While dopaminergic cells are mainly located in the SN and VTA, 
dopamine can be further converted into noradrenaline (NA) in other brain regions (i.e., locus 
coeruleus). Therefore, the use of conventional TH immuno-histochemical methods98 is 
inadequate to the purpose of discerning between catecholaminergic99 cells (i.e., DA and NA). 
Thus, anatomical distribution of catecholaminergic neurons and their targeted areas becomes 
a key element in the interpretation of any results based on TH staining.  
This anatomical consideration is particularly relevant in the context of this thesis. As 
previously discussed, 6-OHDA administration has a generalized effect on both dopaminergic 
and noradrenergic cells, and although dopaminergic specificity can be achieved through 
desipramine pretreatment, we purposely decided not to pre-treat animals as noradrenergic 
deficit may underline a variety of PD-related NMS. For instance, noradrenaline in the basal 
forebrain promotes wakefulness, in the amygdala it is involved in response to stressful 
stimuli, and in the thalamus it modulates the sensation of pain100–104 (for review103).  
The method used to map TH immunoreactivity relies on a holistic approach by co-registering 
full coronal section images, taken on an epifluorescence microscope, to the Allen mouse 
brain atlas. It allowed us to gather information on more than 170 regions within the mouse 
brain (n = 5/group for a total of 312 coronal sections). With this approach, we were able to 
confirm the lesioning effect initially observed in the SN, hippocampus and locus coeruleus. 
Moreover, we detected a variety of affected areas not previously described (fig.4). 
Although the main target of the dopaminergic fibers originating in the substantia nigra pars 
compacta (SNc) is the striatum (STR dorsal part), a portion of these fibers targets the globus 
pallidus (GP)106. With fibers arborizing profusely in the GPi (internal part) and more sparsely 
the GPe (external part)107–110. Accordingly, lesions to the SNc in both rodents and monkeys 
cause a reduction in dopamine levels within the GP and a relatable reduction in TH 
immunoreactivity111–113. Some of these fibers pass through the pallidum en route to the 
striatum, and innervate both regions. These fibers are likely affected by our protocol. Still, 
retrograde and anterograde labeling studies have shown that some dopaminergic fibers arise 
as a nigropallidal projection separately from the nigrostriatal projection114–117. Nigropallidal 
fibers are conceivably not damaged by our lesion protocol. 
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Figure 4.  Lesion mice were perfused and their brains dissected for immunohistochemistry. Coronal sections 
throughout the brain were cut at the vibratome and stained for Tyrosine hydroxylase. Images were co-registered 
to the Allen mouse brain atlas and staining was quantified via a Matlab custom made script. (a) Line graph 
shows the normalized z-score staining values from rostro-caudal direction (fit line), in Sham and Lesion mice, 
where circles represent specific sample values. The graph was superimposed to a sagittal image of the mouse 
brain to aid interpretation. (b) Bar graph shows the 6-OHDA induced cell loss in Lesion mice, expressed as cell 
counts (% of control mice) for the substantia nigra pars compacta (SNc, left) and the neighboring ventral 
tegmental area (VTA, right). (c) Bar graph shows the catecholaminergic loss in Lesion mice expressed as TH 
staining intensity (% of control mice) within basal ganglia regions [(striatum (STR) dorsal part, substantia nigra 
pars reticulata (SNr), globus pallidus external and internal part (GPe, GPi)]. Mann-Whitney test, * p < 0.05, ** p 
< 0.01; n = 5/group. Data presented as mean ± SEM. Nomenclature and acronyms follow Allen atlas 
specifications105. 
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The subthalamic nucleus receives sparse collaterals from the SNc, as shown by studies in 
rats118, monkeys116 and humans119. Though characterized by low density of DA axons, it has 
been shown that the nigrosubthalamic pathway can directly modulate the activity of 
subthalamic neurons and that this pathway is subject to degeneration in MPTP-treated 
monkeys112, and in our mouse model. 
The dendrites of SNc dopaminergic neurons radiate ventrolaterally into the substantia nigra 
pars reticulata (SNr). Dopaminergic release in this area differs from the other basal ganglia 
nuclei because it is dendritic, rather than axonal120–122. It has been shown that the interaction 
of dendritically released DA with somatodendritic autoreceptors regulates DA cell activity 
and may also affect SNr neurons (those are GABAergic). However, SNr neurons lack 
postsynaptic DA receptors, making it unclear how locally released DA modulates their 
activity. 
Notably, significant reductions of dopamine in the globus pallidus, subthalamic nucleus and 
SNr have been reported in postmortem studies on brain tissue from PD patients123 and in our 
mouse model a reduction in TH immunoreactivity indicates a similar phenotype. 
The nucleus accumbens is located in the ventral striatal formation and receives 
dopaminergic projections from the ventral tegmental area (VTA). This pathway is directly 
involved in reinforcing and addictive responses that initiate drug addiction124–127 (for 
review128). Interestingly, recent studies have highlighted the occurrence, in PD patients, of 
behaviors that develop as non-motor side effects of prolonged dopamine replacement therapy 
(i.e., addiction and perseverative features). In our PD model, we initially did not observe 
differences in TH immunoreactivity between sham and lesioned accumbal areas (as shown in 
fig.4c). However, a detailed analysis of shell and core129 sub regions, highlighted that there is 
a reduction in TH fibers restricted to the shell but not the core of the nucleus accumbens (data 
not shown).  Dopamine release in the shell and the core region serve distinct functions, with 
the shell mediating the association between sensory stimulus and unpredicted rewards, while 
the core works as an interface between motivation and action (for more125). Further studies in 
our research group aim at understanding possible implications of dopamine replacement 
therapy on the development of addictive-like behaviors.  
The abovementioned examples show how an anatomically resolved lesion map can 
potentially uncover Parkinson disease-relevant structures and offer researchers a practical 
framework for future investigations. Importantly, the method used here has the holistic 
approach usually associated to high technological demands, yet our method relies on the use 
of common epifluorescence microscopes and a Matlab script to co-register the images with 
the Allen atlas. Though it increases workload, due to the necessity of individually co-
registering images, the process can be applied with low technical demand.  
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3.3 MOTOR DOMAIN CONTROL EXPERIMENTS (Paper I) 
As discussed above, the PD symptomatology involves both motor and non-motor symptoms. 
The ability to model one or the other of these classes of deficits is challenged by the 
significant, although not complete, overlap between the brain areas and mechanisms that 
underlie them. On the other hand, the progressive nature of the disease and the differential 
onset of these symptoms suggest that NMS can be modeled in animals by inducing only a 
partial neuronal degeneration. In preclinical models of PD, a correlation between the 
magnitude of cell loss in the substantia nigra and the degree by which spontaneous 
movements are affected has been observed (see for instance130). As previously mentioned, 
motor impairment in preclinical research represents a potential hinder for the study of NMS, 
which relies on behavioral tests where the ability of the mice to move must be for the most 
part intact.  
Based on these considerations and in order to validate our NMS model, we carefully 
examined the effects produced by our 6-OHDA lesion on a number of motor paradigms. Our 
results showed that the partial bilateral lesion of the striatum does not affect spontaneous 
locomotion, measured in the novel home cage test69 and the open field test131,132.  
Successively, we have also run a variety of  tests specific to the motor domain, which are 
known for their higher sensitivity, such as gait analyses131, cylinder test69, grip strength and 
rotarod (data not published). 
In PD patients, spontaneous movements, particularly those of automatic nature, show 
slowness in execution. For instance, patients can present reduced speed (i.e., hypokinesia), 
when initiating and executing a single movement and progressive reduction of its amplitude, 
up to complete cessation133–136. These features are common in parkinsonism because the basal 
ganglia are involved in the performance of automatic movements such as gait85. Gait is 
affected by several hypokinetic features including reduced stride length and decreased off-
ground elevation of the feet, leading to short stepping and shuffling, which are associated 
with reduced arm swinging and predominance of flexor posture59. 
A comprehensive gait analysis using ventral plane videography showed that partially lesioned 
mice had normal stride length and frequency but presented subtle impairments of gait 
dynamics affecting specifically the hindlimbs (table1&fig.1, Paper I).  
Next, we tested the effect of the lesion on motor learning and motor coordination by using the 
rotarod test, where the mice are placed on a circular rod rotating at a fixed or increasing 
speed and the latency to fall is measured. While the fixed-speed paradigm is generally used to 
assess motor learning, the accelerating protocol is considered a better approach to measure 
motor coordination (know-how137–140) (fig.5). In short, on day 1 the animals were familiarized 
with the apparatus during three consecutive trials at a fixed speed of 4 rpm (i.e., rotation per 
minute). Upon 2 h resting interval, mice were returned to the rod and latency to fall was 
measured at different fixed-speed values with increasing task difficulty. On day 2 mice were 
again tested on a fixed-speed protocol with higher rpm range. Two-way RM ANOVA 
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showed no interaction between groups and speed throughout the test (F9,126 = 1.84, p = 0.07), 
indicative of no motor learning deficits (fig.5b). On day 3, mice were tested with the 
acceleration protocol, in which the rod speed increased from 4 to 38 rpm within 5 min. In this 
test, Lesion mice showed lower latency to fall when compared to controls (p < 0.0001, 
Student’s t-test, two-tailed). The parsimonious explanation of why Lesion mice only fail on 
the acceleration version of the rotarod test is that subtle alterations in gait dynamics affect 
coordination and cause animals to fall. This effect is only observable when the task requires 
constant adaptation to changes in speed. 
 
 
Figure 5. Comparison between two rotarod test protocols used to assess motor performance in mice. (a) 
Schematic experimental timeline. Animals were first trained on the rotarod apparatus in three consecutive trials 
with a fixed speed of 4 rpm. Upon a 2 h resting interval mice were tested at different fixed speeds (4, 7, 10 and 
14 rpm). On day 2 mice were tested again at 14 rpm and then at a higher range of speeds (19, 24, 31, 34 and 38 
rpm). On day 3 mice were tested according to the acceleration protocol, where the rod speed progressively 
increased from 4 up to 38 rpm within 5 min. (b) Line graph showing latency to fall (sec) during the fixed speed 
test on day 1 and 2 for each speed tested, in Sham and Lesion mice. (c) Bar graphs showing performance during 
the accelerating version of the rotarod test measured as latency to fall (sec, left panel) and speed with which it 
occurred (rpm, right panel). Two-tailed Student’s t-test; **** p < 0.0001; n = 8/group. Data presented as mean ± 
SEM. 
 
We previously reported that 6-OHDA lesioned mice have a significant reduction in the total 
number of rearing events as assessed with the cylinder test69. This data was later corroborated 
by counting rearing events during the open field test (data not shown). The observed 
reduction in rearing was therefore detected in two different apparatuses and interpreted as an 
example of forelimb hypokinesia. In order to exclude the possibility that such hypokinesia 
was due to muscle weakness, also present in PD patients141, we performed the grip strength 
test142. Our results showed that Lesion and Sham mice performed similarly on the grip 
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strength (3 trials avg, p = 0.80; max strength, p = 0.91, Student’s t-test, two-tailed, n = 
12/group) leading us to exclude muscular weakness, a feature associated to higher disease 
severity in PD patients141. 
In conclusion, the model employed in this study reproduces an initial stage of symptomatic 
PD, with no effect on spontaneous locomotion. We believe that the subtle alterations in gait 
dynamics do not represent a potential hinder to the study of NMS. We did observe a 
reduction in vertical movements (rearing), in absence of muscle weakness. To compensate for 
this particular deficit, we modified some of our behavioral tests. For instance, we lowered the 
position of the odor source during olfactory discrimination tests (see below).  
 
3.4 OLFACTORY DYSFUNCTION (Paper I) 
The association between olfactory dysfunction and development of PD was first suggested in 
1975 by Ansari and Johnson143. By testing the olfactory threshold for amyl acetate in PD 
patients, the authors described for the first time a clear correlation between disease 
progression and loss of olfactory acuity. Remarkably, olfactory deficits were also reported in 
asymptomatic relatives of patients with PD, some of whom later developed the disease144. 
Remarkably, most patients report a decline in their sense of smell and olfactory impairment is 
clinically confirmed in up to 90% of PD patients145–147. Although olfactory dysfunction is one 
of the most frequent non-motor symptom, it remains one of the least understood148. 
Olfactory dysfunction is not severely disabling and it is relatively nonspecific149 (up to one-
third of the elderly population has olfactory loss), limiting its utility as a predictive feature of 
the disease. Nevertheless, given Braak´s observation that the olfactory bulb is one of the first 
regions of the central nervous system to be affected in PD150, it is important to consider this 
as a strategic area of research, since it may help to define features for early diagnosis (when 
combined with more specific prodromal symptoms). 
PD is a neurodegenerative disease, but paradoxically, olfactory deficit may be a consequence 
of dysregulated neurogenesis.  
In the adult olfactory bulb, neurogenesis continuously replaces older neurons that die and this 
is particularly relevant to the generation of new interneurons151. Interfering with this process 
affects olfactory discrimination152,153, including odor-dependent responses, such as fine 
discrimination and short-term spontaneous memory of odorant cues154–159. In the brain of PD 
patients, an increased number of dopamine interneurons is found in the glomerular layer of 
the main olfactory bulb (MOBgl), a feature that has been replicated in preclinical research160–
165. Importantly, dopaminergic MOBgl neurons play an inhibitory role (they are indeed 
GABAergic but capable of releasing dopamine) in the olfactory circuit148 and their excessive 
number is believed to be responsible for the observed olfactory deficits in PD.  
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The mechanism of this upregulation is linked to alterations in neural progenitor cells in the 
subventricular zone (located in the vicinity of the striatum, surrounding the lateral ventricles), 
which continuously provides the olfactory bulb with newly generated cells166. In the PD brain 
neurogenesis is reduced, yet the net effect in the MOBgl is an increase in DA interneurons. 
The causal links between these events are not yet fully understood. 
Interestingly, olfactory dysfunction in PD is not responsive to dopaminergic replacement 
therapies167. Thus, patients can undergo years of treatment with L-Dopa and yet continue to 
show olfactory dysfunction. In accord, L-Dopa treatment normalizes decreased neurogenesis 
in the adult brain of 6-OHDA unilaterally lesioned mice but does not correct for the increased 
number of dopaminergic MOBgl cells168. Similarly, prolonged treatment with the non-
ergoline dopamine D2 / D3 agonist pramipexole169, normalizes neurogenesis in the adult 
brain of PD rodent models, increasing the number of newly generated neurons in the 
olfactory bulb (6-OHDA lesioned mice168 and rats170), with unknown effect on dopaminergic 
cell numbers within the MOBgl. The MAO-B inhibitor, selegiline, has been found to increase 
the number of newly generated neurons and normalizes the number of dopaminergic cells in 
the MOBgl (6-OHDA lesioned mice167), however no studies have conclusively shown 
whether either of those treatments can result in olfactory recovery.  
In summary, a growing body of literature is pointing to aberrant neurogenesis as the causal 
factor in PD olfactory deficit. Some of the drugs used for dopamine replacement therapies 
positively affect neurogenesis but not necessarily normalize the dopaminergic MOBgl cell 
numbers. These observations remain compartmented due to the lack of suitable preclinical 
models to examine the effect of therapeutic interventions on anatomical changes underlying 
olfactory performance. In order to test whether our mouse model could be used to study 
olfactory dysfunction in PD, we examined the olfactory discriminative ability of 6-OHDA 
Lesion and Sham mice.  
When a mouse is exposed to a novel odor, it explores the odor by sniffing171. With repeated 
presentations of the odor, the animal spends progressively less time exploring it (habituation). 
Thus, we measured habituation, as well as the tendency to explore for a longer period of time 
a new odor (dishabituation)172 when animals were presented to different odors. We selected 
two categories of odors; non-social (e.g., neutral) and social (that carry biological meaning, 
e.g., used as a mean for intra-species communication). This approach allowed us to detect 
olfactory discriminative impairment in our PD model, consisting in the inability to recognize 
an odor as novel within categories (fig.2, Paper I). In line with these results, the olfactory 
deficit described in PD patients is often manifested as lack of ability to distinguish between 
odors147. 
Our observations are in line with what was described in a PD mouse model based on 
overexpression of human α-synuclein, which discriminates between strongly different scents, 
but lacks the ability to distinguish between different citrus odors173. However, the α-synuclein 
overexpressing mouse model of PD develops, in parallel, a variety of symptoms constraining 
the timeline of studies that entail prolonged treatments, which are necessary for the study of 
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neurogenesis. Thereafter, our mouse model allows the experimenter to potentially observe the 
effect of drugs on neurogenesis and assess its effect on olfactory performance. 
 
3.5 CIRCADIAN RHYTHM ALTERATIONS (Paper II) 
Disturbances of daily pattern of sleep-wake cycle are consistently documented in PD 
patients174. For example, many patients experience symptoms of insomnia and excessive 
daytime sleepiness175–178 which are not responsive to L-Dopa treatment179. Excessive daytime 
sleepiness, as opposite to wakefulness (i.e., alertness), has been extensively studied by Arnulf 
and colleagues180, who suggested that circadian dysfunction is a key component of the non-
motor PD symptomatology. In a recent review, David Willison181 described sleep disorders as 
nearly ubiquitous among PD patients and highlighted that those disturbances manifest early 
during the disease. The potential impact of a disrupted circadian system in PD has received 
relatively little attention in the literature yet it may be a contributing factor to the severity of 
other NMS. 
The role of DA in the regulation of circadian clock function is now well-established. Both in 
non-human primates and rodent models, DA loss is associated with a disruption of sleep 
architecture182–185, including fragmentation and onset variability of rest vs awake states186,187. 
Concomitantly, DA is known as an important wake promoting factor across species188,189 and 
dopaminergic availability has been linked to circadian clock function with DA transmission 
exhibiting daily rhythms of activity190,191 and extracellular levels of DA affecting the patterns 
of striatal clock gene expression192 and neuronal excitability. 
Changes in the circadian rhythm have been investigated in different animal models of PD, 
highlighting a correlation with DA degeneration. While MPTP-treated mice183, which exhibit 
approximately 50% loss of dopaminergic neurons, do not show disruption of the circadian 
rhythm183,193, the MitoPark mice194, which have a progressive DA loss195, show both motor 
deficits and circadian rhythm disruption at about 20 weeks of age (corresponding to ~60% 
loss of DA midbrain neurons). In these mice, the age-dependent decline affects the amplitude 
as well as the stability of the circadian rhythm, coupled with an increased fragmentation of 
day/night activities. If the circadian system is challenged by exposure to constant darkness, 
normal animals retain a robust free-running circadian locomotor rhythm, whereas MitoPark 
mice lose periodicity (referred to as arrhythmia). Upon re-exposure to light-dark cycle, 
locomotor rhythm is restored186. In agreement with the results obtained in MitoPark mice, rats 
with a unilateral 6-OHDA lesion191, VMAT2-deficient mice196 and the α-synuclein  
overexpressing197 transgenic mice also show lower night-time activity (rodents are nocturnal) 
and in some cases fragmentation during sustained darkness198. 
In line with these observations, we found that in our mouse model the bilateral partial lesion 
disrupts the circadian rhythm and affects the spontaneous motility of the animals during the 
active (i.e., dark) phase of the 24 h cycle, as measured by reduced movement in the activity 
monitoring home cage (fig.1, Paper II). 
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The light-dark cycle strongly influences the daily pattern of behavior, often over-riding the 
expression of underlying circadian rhythms controlled by the endogenous clock genes199 (i.e., 
entrainment). We decided to study the endogenous circadian rhythm by analyzing 
spontaneous motility in the free running state. This assessment requires animals to be 
exposed to constant conditions in absence of cyclic environmental cues, such as light200. We 
found that our mouse model displays a disruption of the endogenous circadian rhythm, as 
indicated by the severe fragmentation of the activity pattern observed when Lesion mice are 
kept in constant darkness (fig.2, Paper II) (know-how on analysis of rhythmicity search for 
Refinetti R.). 
Circadian rhythm and wakefulness are regulated by histamine201–203, which is widely 
expressed throughout the brain and participates in the regulation of basic homeostatic 
processes and multiple brain functions. Among the four histamine receptors, the H3 receptor 
(H3R) has received considerable attention as a target for the treatment of sleep 
disorders202,204–207. H3Rs are located presynaptically, where they reduce histamine synthesis 
and release208,209. Administration of H3R antagonists/inverse agonists, such as thioperamide, 
has been shown to improve wakefulness in animal models of narcolepsy and in narcoleptic 
patients207,210–212. Thus, we tested thioperamide for its ability to revert dysfunctional circadian 
rhythm observed in our mouse model of PD. Our results indicate that subchronic treatment 
with thioperamide restores normal motor activity during the active phase of the circadian 
rhythm and highlights the potential efficacy of this drug for the treatment of sleepiness and 
reduced wakefulness in PD patients (fig.3, Paper II). 
 
3.6 COGNITIVE DEFICITS (Papers II and III) 
Cognition can be measured within different functional domains. For example, while attention 
is commonly assessed by parameters such as reaction time and vigilance, memory regards the 
processing of new information and is usually evaluated in recognition and executive memory 
tests. Other cognitive functions are very specific, like visuospatial analysis and orientation or 
use of language (verbal fluency and naming). When dysfunctional, all these mental capacities 
fall under the umbrella of cognitive deficit and are clinically classified on a growing 
spectrum, from mild-to-dementia, depending on how much they interfere with everyday life. 
Cognitive dysfunctions, such as those listed above, are common in PD. Mild cognitive 
impairment affects a quarter of patients in the early stages of their disease213,214, and 
approximately half reach dementia by 10 years from diagnosis215. However, the pattern of 
cognitive impairments and their speed of evolution vary markedly between individuals216. 
Some patients progress rapidly to dementia while others have slower time courses (related to 
age at onset of PD and strongly correlated to familial forms of the disease217). PD patients 
that develop cognitive dysfunction are usually affected in at least one cognitive domain218 
prior to the emergence of motor symptoms219–221. 
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In the preclinical research, the assessment of cognitive function is generally done in two 
steps. Initially, the animal is presented to stimuli and then to a novel condition in which the 
prior stimuli presentation serves as a guide for prospective behavior. The stimuli can belong 
to any sensory modality, be it visual, tactile or spatial and the novel condition can be the 
presence of novel cues, new contexts or locations. The prospective behavior will be 
dependent on natural evolutionary traits and, in the case of rodents, usually relies on their 
‘unconditioned preference’ for novelty222. Thus, when exposed to a familiar object alongside 
a novel object, rodents approach and spend more time exploring the novel object. This 
indicates that a representation of the familiar object exists in memory, allowing the rodent to 
attribute novelty to the new object. The commonly used novel object recognition (NOR) test 
is based on these pre-requisites. The test consists of a training phase where the animals are 
presented with two similar objects, and following an interval, one of the objects is replaced 
with a novel object, and  the exploratory behavior (time spent investigating the objects) is 
measured223. The NOR test is prone to a variety of conditions under which results can be 
misleading. For instance, the choice of objects must be based on perceptual cues that are 
relevant for rodents, not humans224. The environment should not be aversive or contain 
unnecessary cues that could compete for attention (i.e., any novel feature will result in 
‘unconditioned preference’). Furthermore, the ‘cognitive load’ of this test is dependent on 
time (e.g., interval between training and test phase).  
The short nature of this test and its proven sensitivity to detect cognitive changes in our 
mouse model (discussed on section 1.6), encouraged us to use the same protocol in multiple 
occasions and proved it to be a useful method for the assessment of drug efficacy.  
As discussed above, clinical and preclinical evidence indicates that the degeneration of 
midbrain dopaminergic neurons occurring in PD affects a number of forebrain structures, 
including the hippocampus225, which is critically involved in plastic processes underlying 
memory. In particular, novelty activates the dopaminergic mesocorticolimbic pathway226, 
giving rise to the hypothesis that it modulates hippocampal memory227,228, through  D1 
receptors and transcriptional regulation of plasticity-related genes229–232. Note that, although 
triggered by novelty, DA in the hippocampus differs from the error-detection role it serves in 
the ventral striatum233,234.  
In the initial study published by our research group, it was shown that the bilateral 6-OHDA 
lesion impaired long-term novel object recognition and decreased long-term potentiation 
specifically in the dentate gyrus of the hippocampus. These abnormalities were reverted by 
administration of L-Dopa, or the D1 receptor agonist SKF81297, but not by the treatment 
with the D2 / D3 receptor agonist, pramipexole69. 
In Paper II we extended this study and further characterized the effect of 6-OHDA lesion on 
higher brain functions, by analyzing gamma oscillations in the hippocampus. Hippocampal 
oscillatory activity has been associated to several cognitive functions, including long-term 
memory encoding and recall235, facilitation of synaptic plasticity236, and maintenance of 
selective attention237. Interestingly, we found that the bilateral 6-OHDA lesion disrupts 
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hippocampal gamma oscillations. Given the involvement of the histaminergic system in the 
modulation of cognitive-relevant oscillatory activity, we also examined the effect of the H3R 
antagonist thioperamide on hippocampal gamma oscillations. We found that thioperamide 
prevents the impairment of recognition memory caused by the 6-OHDA lesion and corrects 
the deficit in gamma oscillation. Our work proposes the involvement of disrupted gamma 
oscillations in PD cognitive deficit (fig.4a&5, Paper II).  
In Paper III we used our mouse model to evaluate the involvement of the mammalian target 
of rapamycin (mTOR) signaling pathway on multiple NMS, including memory. mTOR is the 
key catalytic component of two large multimeric complexes, mTOR complex 1 (mTORC1) 
and 2 (mTORC2)238. Whereas, mTORC1 regulates a variety of cellular functions, including 
cell growth and proliferation, autophagy and protein synthesis, mTORC2 participates in the 
control of cytoskeletal dynamics and cell size. 
We focused on mTORC1 signaling, because it has been shown to be required for 
hippocampal long-term potentiation, memory formation and consolidation239,240. Two of the 
main downstream targets of mTORC1, the ribosomal protein S6 kinase (S6K) and the 
eukaryotic initiation factor 4E-binding protein (4E-BP), promote mRNA translation via 
activation of downstream initiation and elongation factors241–243. Activation of these signaling 
components modulates synaptic plasticity and affects cognition through spatial and temporal 
coordination of protein synthesis.  
Excessive activation of mTORC1 is linked to intellectual disabilities244, including tuberous 
sclerosis245,246 and Down syndrome247. Notably, the cognitive impairment observed in animal 
models of these two conditions is counteracted by rapamycin, a selective inhibitor of 
mTORC1245,246,248. We found that subchronic administration of rapamycin, which effectively 
reduces mTORC1 activity in the brain249, abolishes the memory impairment produced by a 
partial lesion of the dopamine system. Rapamycin acts by preventing the phosphorylation of 
S6K and 4E-BP, which in turn regulate two parallel signaling branches implicated in the 
control of protein synthesis and in multiple aspects of synaptic plasticity and memory. Our 
results indicate that selective inhibition of S6K with PF-4708671 is sufficient to rescue 
memory performance (fig.1, Paper III).  
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3.7 AFFECTIVE DISORDERS 
Anxiety and depression affect up to 45% of PD patients and are among the most 
invalidating219 NMS. Unfortunately, L-Dopa efficacy on mood-related dysfunctions is limited 
and independent reports indicate that its chronic administration might even be correlated with 
the emergence of depression and anxiety250–255.  
3.7.1 Depression (Papers I and III) 
The profile of depressive symptoms observed in PD patients is not identical to that reported 
in primary depression. Distinctive features of PD-related depression include elevated levels 
of dysphoria, irritability, and suicidal ideation, albeit not accompanied by increased suicide 
rate. Diagnosis of depression in PD is complicated by its overlap with other symptoms. For 
instance, lack of concentration and fatigue can also be observed in non-depressed PD 
patients, and symptoms such as psychomotor slowness may be independent from depression 
and rather result from neurological motor deficits256–259. Despite increasing efforts in the 
study of depression in PD patients and the availability of preclinical models, PD-related 
mood disorders are still difficult to treat. Studies have shown that a significant percentage of 
patients do not respond to 1 or more trials of pharmacotherapy, suggesting inadequacy of 
antidepressant choice260. In this regard, preclinical models are critical to identify neuronal 
mechanisms underlying these symptoms, screen for new drug options and test for drug-drug 
interactions. 
Depressive-like behavior and antidepressant efficacy can be studied in rodents with the 
forced swim test (FST), developed by Porsolt261 et al. in 1977. This classic paradigm is 
based upon the evaluation of immobility, as a measure of ‘behavioral despair’, which rodents 
display when placed in a container filled with water from which they cannot escape (know-
how262–265). Another popular test is the tail suspension test (TST), which consists of a simple 
set-up in which mice are suspended by their tail and the time spent in immobility is measured 
(know-how266). The FST and TST show sensitivity to all major classes of pharmacological 
antidepressants, including desipramine, imipramine, atypical antidepressants (e.g., bupropion 
and citalopram), and SSRIs, such as fluoxetine and paroxetine (FST267,268, TST269). However, 
both the FST and the TST represent an acute situation and do not mimic the temporal features 
of onset, persistence, and therapeutic effects of clinical depression in patients268. An 
alternative approach is to measure anhedonia270, a core symptom of depressive disorder, 
characterized by the loss of interest in activities that are otherwise regarded as pleasurable. In 
rodents, anhedonia is typically measured with the sucrose preference test271,272 (though 
saccharin is a preferable choice). In this test animals are offered access to two water bottles, 
one of which contains sweetened water. Rodents naturally favor sweetened liquids as 
measured by preferential liquid intake. 
In this thesis, we present evidence that our mouse model of PD is a valid tool for the study of 
depression-like phenotypes associated with PD. We employed the aforementioned behavioral 
tests and showed that bilateral partial DA lesion induced by 6-OHDA results in increased 
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immobility in the FST and TST (fig.3, Paper I; fig.2b, Paper III). Moreover, we also show 
that depressive-like behavior is observed in mice pretreated with desipramine, indicating that 
this condition is dopamine-related (fig.6a, Paper I). These findings are in line with previous 
work performed in the 6-OHDA-lesioned rat38,67,273,274, and in other murine models of PD, 
such as the MPTP-treated and VMAT2-deficient mice196,275,276. Furthermore, by using the 
sucrose preference test we found that the 6-OHDA lesion prevents the mice from developing 
preference for saccharin over the course of a three-day experiment, indicative of anhedonia 
(fig.6). 
 
 
Figure 6.  Measurement of anhedonia on control, sham-operated, and 6-OHDA lesioned mice (n = 8/group). 
Mice were first acclimatized to experimental cages for one-week (habituation) prior the experiment, and baseline 
preference was measured as percent (%) of volume intake from bottle 1 or 2, both filled with water (see 
description of the apparatus on Paper II). Subsequently, mice were offered 0.5% saccharin in only one of the 
bottles for three consecutive days. Liquid intake and visits to each bottle were measured. (a) Bar graph shows 
that over the 4 days period, Lesion mice made less visits to water source than Sham mice, in agreement with 
circadian data (*** p < 0.001, Student’s t-test, two-tailed). (b) Bar graph shows that although Lesion mice make 
less visits to water bottles, both groups have similar total liquid intake (ml) (p = 0.61, Student’s t-test, two-
tailed). (c) Line graph shows the time course of preference for saccharin, expressed as % of saccharin intake/total 
intake. Note the development of preference for saccharin in Sham mice, reaching almost 100% preference within 
the 3 days of exposure. Whereas, Lesion mice remained close to 50% which is an indication of anhedonia (Two-
way RM ANOVA, interaction effect, F3,42 = 7.21, *** p < 0.001, followed by Sidak’s multiple comparison; 
between groups, ** p < 0.01, *** p < 0.001).  Data presented as mean ± SEM. 
 
In PD, mood-related NMS appear to be dopamine-mediated. In patients, the mood 
fluctuations tightly correlate to the “on-off phenomenon”, with depressive symptoms 
increasing during the “off” L-Dopa periods277. Thus, unless there is a good control of the 
fluctuations caused by treatment with L-Dopa, antidepressant therapy will remain 
suboptimal277. In this context, drugs acting preferentially on dopamine D2 / D3 receptors, 
such as pramipexole, represent a potential alternative to L-Dopa, since they have been shown 
to reduce depression and anxiety in clinical trials278,279. 
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Common antidepressant agents, such as noradrenaline and serotonin reuptake inhibitors, have 
also been tested in parkinsonian patients. For instance, tricyclic antidepressants acting on 
noradrenaline reuptake, such as desipramine and reboxetine, as well as citalopram, a selective 
serotonin reuptake inhibitor, reduce depression associated to PD259,280. Similarly, 
nortriptyline, which blocks noradrenaline and serotonin reuptake, reduces depression in PD 
patients, thereby significantly improving their quality of life281.  
In agreement with clinical data, both pramipexole and reboxetine, but not L-Dopa, treatment 
reduced depressive-like behavior in our mouse model (fig.5a&6a, Paper I). Interestingly, 
since the noradrenaline reuptake inhibitor desipramine did not affect the depressive-like 
phenotype observed in our Lesion mice, it is unlikely that reboxetine produces this effect by 
promoting noradrenergic transmission. A more plausible explanation is that reboxetine acts 
by blocking dopamine uptake from noradrenaline terminals, which is particularly efficient in 
extra-striatal regions involved in affective functions, including the cerebral cortex and 
hippocampus73,282. 
Dysregulated mTOR transmission (discussed on section 3.6) is also implicated in affective 
disorders. A current hypothesis is that decreased mTORC1 activity in different cortical 
regions is associated with depression whereas augmented mTORC1 activity, such as that 
produced by the NMDA receptor agonist ketamine, reverts these conditions283–286. However, 
studies in animal models have shown that subchronic administration of rapamycin reduces 
depressive-like behaviors287, prompting further analysis of the actions of this drug on mood 
disorders. In Paper III we used our mouse model to examine the ability of rapamycin and PF-
4708671, two inhibitors of mTORC1 signaling, to counteract depressive-like behaviors 
associated with PD. We found that only rapamycin reduces the depression-like behavior 
manifested by PD mice in the FST, suggesting that the anti-depressant action of rapamycin 
depends on concomitant inhibition of the 4E-BP and S6K signaling cascades. The finding 
that rapamycin reduces depression-like behavior contrasts with previous studies indicating 
that reduced mTOR signaling is associated with depression. In this regard, our results are 
more in line with the observation that subchronic administration of rapamycin, albeit at 
higher doses287 than those used in our study, exerts anti-depressant effects in the FST and 
TST (fig.2, Paper III). 
3.7.2 Anxiety (Papers I, II and III) 
In nature, anxiety is an adaptive response and serves as an alerting signal of impending 
danger, finalized to adjust the behavior and implement appropriate countermeasures288. 
However, anxiety may also be pathological if the symptoms are prolonged, excessive or 
occurring at inappropriate times. Anxiety and depression are sometimes difficult to 
distinguish; however, unlike depression, a core feature of anxiety is the presence of 
apprehension and worry.  
There is increasing evidence that anxiety disorders in PD may be directly related to early 
neuropathological changes289–291 and despite their high prevalence, anxiety disorders are often 
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under-diagnosed and under-treated in PD patients292. In the clinics, anxiety disorders often 
precede or are accompanied by depression (comorbidity) and, in many cases, may persist 
even if depression is successfully treated293.  
In preclinical research, anxiety can be measured through the expression of defensive 
behaviors (i.e., actions the animal takes to reduce threat). Defensive behaviors vary according 
to species and are dependent on environmental features. Distinctions between the expression 
of anxiety and fear are much debated in the literature. For example, when rodents are 
enclosed on a small environment and exposed to a threat they show a freezing response, 
interpreted as fear, but when an “escape” route is available, rodents exhibit anxiety-induced 
avoidance behavior294. Thereafter, behavioral tests for fear or anxiety must take into 
consideration the environmental features and in particular the availability of an “escape” 
route.  
The most widely used and pharmacologically validated procedures for assessing anxiety in 
rodents are the open field (OF) and the elevated plus maze (EPM) tests (know-how295–297). 
The OF assesses anxiety-like behavior by measuring the extent to which the animal avoids 
the center of the arena, which entails risk, and stays close to the walls, a behavior known as 
thigmotaxis. In the EPM rodents are placed on an elevated cross-shaped maze with two open 
arms and two enclosed arms. Rodents naturally avoid the open arms, which entail risk, and 
excessive avoidance is an indicator of anxiety. Anxiety can also be assessed using the light-
dark box test (know-how299). Rodents have innate aversion to brightly illuminated areas and 
the light-dark apparatus consists of a dark “safe” chamber with an open access to an 
illuminated “aversive” chamber. Rodents are initially placed in a dark compartment and place 
avoidance is measured as the latency to visit the brightly lit area298–300. 
We have tested the PD mouse model with the three tests presented above and our results 
showed that 6-OHDA lesion increases thigmotaxis in the OF, reduces exploration of the open 
arms in the EPM and increases the latency to the first exploration of the bright chamber in the 
light-dark box test. These responses are indicative of increased anxiety (fig.4, Paper I; 
fig.4b&c, Paper II; fig.3&4, Paper III). Interestingly, pretreatment with desipramine did not 
modify the anxiogenic effect caused by the 6-OHDA lesion (fig.6b, Paper I), suggesting that 
the loss of nigrostriatal dopaminergic neurons specifically mediates mood-related disorders in 
our model of experimental parkinsonism274.  
In summary, we validated our 6-OHDA mouse model of PD for the study of depression and 
anxiety, behaviors observed in PD patients301–303. Though few publications have shown 
depression and anxiety features in the same PD model (comorbidity), a variety of dopamine 
depleted rodents do manifest increased anxiety-like behaviors67,196,304,305. Tadaiesky et al. 
(discussed on section 1.5) suggested that the anxiogenic response elicited by 6-OHDA could 
be associated with dopaminergic depletion in the prefrontal cortex. This hypothesis is 
supported by previous evidence that 6-OHDA injected directly into the medial prefrontal 
cortex induces a significant anxiogenic effect in rats evaluated in the EPM306.  
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In contrast with the idea of a pivotal role of the prefrontal cortex in PD related anxiety, 
functional magnetic resonance imaging studies suggest that abnormal emotional responses in 
PD patients might be mediated by perturbed dopaminergic input to the amygdala307,308. This 
brain area plays a fundamental role in the acquisition, modulation and expression of 
emotions, being targeted by dopaminergic cells and having wide-spread efferent connections 
to nuclei within the basal ganglia309,310. In the amygdaloid complex, dopamine originates 
from the substantia nigra and ventral tegmental area, which target the main input (basolateral, 
BLA) and output (central, CeA) nuclei of the amygdala (for review311). Interestingly, brain 
wide analyses of TH expression in our mouse model indicate that the dopaminergic 
denervation caused by the 6-OHDA lesion is more prominent in the BLA (data not shown, 
approach presented on section 3.2). Remarkably, it has been shown that whereas the BLA is 
involved in stimulus detection and evaluation of the threatening stimuli linked to anxiety, the 
CeA is involved in the expression of fear behaviors312. 
Our limited understanding of the underlying pathophysiological mechanisms that give rise to 
anxiety is evidenced in the extensive literature containing conceivable factors that could 
explain mood disorders in PD.  
Recent evidence suggests that the noradrenergic and serotonergic systems may play a more 
relevant role in the manifestation of PD-related anxiety than previously thought254. According 
to the Braak staging of PD pathology, serotonergic cell loss in the raphe nuclei is evident 
prior to nigrostriatal dopaminergic degeneration19,313. Serotonergic neurons originating in the 
raphe nuclei provide a massive input to corticolimbic structures involved in the control of 
anxious states, and there are many studies demonstrating that anxiety disorders may be 
caused by serotonin abnormalities288.  
Noradrenaline dysfunction also occurs prior to pronounced degeneration of dopaminergic 
neurons150. Ascending noradrenergic projections from the locus coeruleus heavily innervate 
essentially all corticolimbic regions involved in integrating the response to anxiety. Due to 
noradrenergic cell loss in the locus coeruleus of PD patients19, significant changes in the 
expression of noradrenaline receptors and transporters may cause the development or 
exacerbation of anxiety. Furthermore, lower levels of dopamine and noradrenaline 
transporters in the locus coeruleus are correlated with increased incidence of anxiety in PD 
patients314. While plasma noradrenaline levels are elevated in de novo PD patients315, lower 
levels of dopamine beta-hydroxylase, the enzyme responsible for hydroxylation of dopamine 
to noradrenaline, have been observed in the cerebrospinal fluid of L-Dopa-treated PD 
patients316,317 suggesting that L-Dopa treatment may alter noradrenaline levels. 
In Paper I, we showed that the administration of the dopamine precursor L-Dopa did not 
modify anxiety-like behaviors in our mice, whereas the D2 / D3 receptor agonist, 
pramipexole, efficiently reduced anxiety features in the EPM (fig.5b, Paper I). A similar 
effect was observed following reboxetine treatment, likely mediated by increasing DA 
availability in extra-striatal regions since desipramine pre-treatment did not block the 
anxiogenic effect caused by the lesion (fig.6b, Paper I). 
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In Paper II we tested thioperamide, a drug that corrected circadian dysfunction and exerted 
pro-cognitive effects in our PD mouse model. We pretreated mice with thioperamide before 
the EPM and light-dark box test based on Bahi et al. previously reported evidence that 
administration of an H3R antagonists, which promotes histamine release, counteracts anxiety 
in naïve mice318. However, thioperamide did not affect the anxious phenotype produced by 
partial dopamine depletion (fig.4b&c, Paper II). This highlights the importance of utilizing 
appropriate animal models of disease when assessing the efficacy of therapeutic interventions 
for specific pathological conditions. 
Finally, in Paper III we tested the effect of the mTORC1 inhibitor rapamycin and showed 
that subchronic treatment counteracts the anxiety-like behavior by normalizing the time spent 
by PD mice in the center zone of the OF, thereby reducing thigmotaxis. We also showed that 
rapamycin increases the propensity of PD mice to explore the open arm of the EPM 
apparatus. In parallel experiments, we used the selective S6K inhibitor, PF-4708671, which 
did not produce a reduction of anxiety-like behaviors (fig.3&4, Paper III). These results 
indicate that rapamycin is capable of fully rescuing anxiety-like behavior in a mouse model 
of PD, and that this effect likely requires blockade of multiple downstream targets of 
mTORC1. 
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4 CONCLUSION AND FUTURE PERSPECTIVES 
The diagnosis and, in large part, the treatment of PD are still focused on motor deficits. This 
criterion has likely contributed to the dominance of motor-based animal models for the study 
of this disorder. However, as shown throughout this thesis, the emerging picture of PD is that 
of a multi-system disorder with motor and non-motor features. NMS in PD are highly 
prevalent and include olfactory loss, sleep and circadian rhythm disturbances, cognitive 
deficits, depression and anxiety, among others. While some of these symptoms respond to 
dopaminergic therapies, others are treatment-resistant and represent the current challenge 
faced in the management of PD symptomatology.  
The unmet need for treatments able to counteract NMS highlights the importance of shifting 
the attention from motor models of PD to NMS models. Although PD is a human-specific 
disease, and does not occur spontaneously in animals, some features of PD can be induced in 
laboratory animals through the administration of toxins, such as 6-OHDA. In this thesis, we 
validated a 6-OHDA-mouse model reproducing a wide range of NMS and used it to identify 
new potential therapeutic approaches for PD.  
Our findings shed light on the contribution of the dopamine and noradrenaline systems to 
affective symptoms frequently manifested in PD patients, indicating the prominent role of 
dopaminergic transmission. We also identified histamine H3 receptor antagonists as potential 
drugs for the treatment of circadian rhythm disruption, which is commonly observed in PD. 
Notably, using our model we showed that administration of drugs interfering with the mTOR 
signaling cascade reverts a number of psychiatric symptoms associated with PD. In 
particular, we found that rapamycin, a drug approved for use as an anti-tumoral, reverts the 
memory deficit, as well as depression- and anxiety-like behaviors produced by the 6-OHDA 
lesion.  
The model described in this thesis represents a relatively simple tool to identify specific 
pharmacological approaches for the treatment of NMS. We have shown that a number of 
NMS can be reproduced in this model and we intend to extend this characterization. For 
instance, it will be interesting to test whether the 6-OHDA lesion results in modifications of 
oscillatory activity at cortical and hippocampal level responsible for sleep alterations, such as 
REM sleep behavior disorder. These studies will be particularly important, since oscillatory 
activity during sleep has been proposed to play an important role in memory consolidation319.   
Other studies will be needed to further investigate the use of specific drugs for the treatment 
of psychiatric symptoms affecting PD patients. The finding that rapamycin counteracts 
cognitive and affective deficits points at a large class of substances acting on mTOR and 
related signaling pathways as potential drugs against NMS. Importantly, many of these 
compounds have already been approved for clinical use in other pathologies, thereby 
prompting the analysis of their possible repositioning for the treatment of PD.     
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5 ‘Plain Language’ summary 
Parkinson's disease (PD) is brought on by the 
degeneration and death of the neurons in the part of 
the brain that produces dopamine. It's typically 
discovered with the onset of motor symptoms that 
include hand tremors and body stiffness. Clinicians have 
no final diagnostic test to rely on, so they typically look 
for motor symptoms and then administer medicine to see if they will dissipate. If a patient 
responds to the treatment, that means he/she is very likely to have PD. 
The medicines used to treat these motor symptoms were introduced in the 1960s, and they 
all follow one logic. They aim to replenish dopamine since it is reduced in the brain. There's 
no cure for PD, and these therapies simply control symptoms. Over the course of decades 
researchers worked hard to figure out the best drug cocktail and the more they learnt, the 
more nuances they saw. For example, researchers noticed that people with PD suffer from 
a variety of other conditions which are not strictly motor. They have problems sleeping and 
feel tired all day long, almost all of them lose their sense of smell, some have mild 
dementia and nearly half get depressed or anxious. These and many other conditions are 
what we call non-motor symptoms, they occur in PD patients and truly affect their quality 
of life. The aim of this thesis was to provide scientists with a tool to study non-motor 
symptoms in PD. Such a tool should have as many of the non-motor symptoms as possible 
and those should occur due to a similar cause, meaning that neurodegeneration and lack of 
dopamine were mandatory features.  
Studying PD is difficult because only humans have this condition. Moreover, the workings of 
the brain are very complex and largely mysterious. We had to choose a living organism, and 
this animal should have a complex brain, comparable to our own. We selected the mouse. 
Mice in research have made incredible contributions to medicine because they are in so 
many ways comparable to us (see ethical considerations on p.11).  
We used a toxin called 6-OHDA, this toxin kills the brain cells that produce dopamine and, 
we used it to recreate the mandatory features described above. We carefully made sure to 
inject precise amounts of the toxin into the brain in order to get an animal that would have 
the non-motor symptoms yet be motorically healthy. This was important because animals 
cannot report how they feel. Hence, we need to ‘read’ their body-language and for that we 
rely on movement. 
We showed that our mouse model of PD partially lost its sense of smell, that it behaved as 
if ‘it was tired’ all day long, that it had learning issues and even depressive and anxiety 
features. Thus, we believe this model allows for the study of non-motor symptoms in PD.  
We then used our PD mice to learn why certain medicine help and others don’t. Finally, we 
searched for alternative treatments. We selected drugs that are approved for use in the 
clinics but not currently used for the treatment of PD. This is called ‘repositioning’ and this 
kind of approach cannot be directly used in humans because it risks causing harm. By 
repositioning, we found a new category of drugs that could be used for the treatment of 
non-motor symptoms in PD.  
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